Another second-line agent cabozantinib, a multikinase inhibitor targeting VEGFR1-3, MET, AXL receptor tyrosine kinase, KIT, and RET, was approved by the US FDA in January 2019 for patients with HCC who have been previously treated with sorafenib. Here, KIT is linked to hepatocellular carcinoma.